Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2026)

Sarepta Therapeutics has reported Other Operating Expenses for 11 years, with the latest figure at $109.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 20.78% year-over-year to $109.5 million; the trailing twelve-month figure through Mar 2026 stood at $813.5 million (up 488.81% YoY), and the FY2023 full-year result was $102.0 million, changed N/A from the prior year.
• Other Operating Expenses for Q1 2026 stood at $109.5 million, down from $399.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $399.4 million in Q4 2025, with the low at $31.6 million in Q1 2022.
• Average Other Operating Expenses over 5 years is $130.2 million, with a median of $109.5 million recorded in 2026.
• Year-over-year, Other Operating Expenses soared 170.06% in 2025 and decreased 20.78% in 2026.
• Tracing SRPT's Other Operating Expenses over 5 years: stood at $31.6 million in 2022, then surged by 222.57% to $102.0 million in 2023, then sank by 49.84% to $51.2 million in 2024, then surged by 680.66% to $399.4 million in 2025, then slumped by 72.59% to $109.5 million in 2026.
• The last three Other Operating Expenses figures came in at $109.5 million (Q1 2026), $399.4 million (Q4 2025), and $151.5 million (Q3 2025), per Business Quant data.

Peer Comparison